338 related articles for article (PubMed ID: 37068157)
1. The future of fertility preservation for women treated with chemotherapy.
Alesi LR; Nguyen QN; Stringer JM; Winship AL; Hutt KJ
Reprod Fertil; 2023 Apr; 4(2):. PubMed ID: 37068157
[TBL] [Abstract][Full Text] [Related]
2. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
3. Ovarian damage from chemotherapy and current approaches to its protection.
Spears N; Lopes F; Stefansdottir A; Rossi V; De Felici M; Anderson RA; Klinger FG
Hum Reprod Update; 2019 Nov; 25(6):673-693. PubMed ID: 31600388
[TBL] [Abstract][Full Text] [Related]
4. Do cancer therapies damage the uterus and compromise fertility?
Griffiths MJ; Winship AL; Hutt KJ
Hum Reprod Update; 2020 Feb; 26(2):161-173. PubMed ID: 31863097
[TBL] [Abstract][Full Text] [Related]
5. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
6. Fertility after breast cancer treatment.
Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
[TBL] [Abstract][Full Text] [Related]
7. The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.
Del Castillo LM; Buigues A; Rossi V; Soriano MJ; Martinez J; De Felici M; Lamsira HK; Di Rella F; Klinger FG; Pellicer A; Herraiz S
Hum Reprod; 2021 Aug; 36(9):2514-2528. PubMed ID: 34333622
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents.
Roness H; Kalich-Philosoph L; Meirow D
Hum Reprod Update; 2014; 20(5):759-74. PubMed ID: 24833728
[TBL] [Abstract][Full Text] [Related]
9. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes.
Nguyen QN; Zerafa N; Liew SH; Findlay JK; Hickey M; Hutt KJ
Mol Hum Reprod; 2019 Aug; 25(8):433-444. PubMed ID: 30953068
[TBL] [Abstract][Full Text] [Related]
11. GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation.
Valsamakis G; Valtetsiotis K; Charmandari E; Lambrinoudaki I; Vlahos NF
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216409
[TBL] [Abstract][Full Text] [Related]
12. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
13. Preserving Oocytes in Oncofertility†.
McClam M; Xiao S
Biol Reprod; 2022 Feb; 106(2):328-337. PubMed ID: 35040934
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity.
Cho HW; Lee S; Min KJ; Hong JH; Song JY; Lee JK; Lee NW; Kim T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096794
[TBL] [Abstract][Full Text] [Related]
15. Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
Horicks F; Van Den Steen G; Gervy C; Clarke HJ; Demeestere I
Mol Hum Reprod; 2018 Apr; 24(4):221-232. PubMed ID: 29438534
[TBL] [Abstract][Full Text] [Related]
16. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
18. Can Some Anticancer Treatments Preserve the Ovarian Reserve?
Vallet N; Boissel N; Elefant E; Chevillon F; Pasquer H; Calvo C; Dhedin N; Poirot C
Oncologist; 2021 Jun; 26(6):492-503. PubMed ID: 33458904
[TBL] [Abstract][Full Text] [Related]
19. Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.
Ottolina J; Mangili G; Sigismondi C; Vanni VS; Viganò P; Candiani M
Gynecol Endocrinol; 2014 Nov; 30(11):778-80. PubMed ID: 25034573
[TBL] [Abstract][Full Text] [Related]
20. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors.
Knobf MT
Oncologist; 2006 Feb; 11(2):96-110. PubMed ID: 16476831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
